Organization (Industry)
ASTRAZENECA PLC
ClinicalTrials.gov lists ASTRAZENECA PLC as lead sponsor of 3,487 trials, counting the companies grouped under it. ASTRAZENECA PLC itself has 1,670 active development programs and 372 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 170 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 210 in 2026 and about 220 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (100 to 500), forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. 4 trials are registered to start in 2027 or later.
This page covers ASTRAZENECA PLC and 1 company grouped under it: 3,487 lead-sponsored trials (3,487 its own, 0 in the grouped companies) and 26 legal-entity registrations (25 its own, 1 in the grouped companies).
Companies grouped under this page (1)
| Company | Lead trials | Legal entities |
|---|---|---|
| ASTRAZENECA PHARMA INDIA LIMITED | 0 | 1 |
Disease areas (525)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Diabetes Mellitus | 454 |
| Lung Neoplasms | 420 |
| Diabetes Mellitus, Type 2 | 382 |
| Asthma | 364 |
| Carcinoma, Non-Small-Cell Lung | 316 |
Showing 5 of 525 disease areas.
Trials by start year as sponsor or collaborator (34)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 4 trials are registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 170 |
| 2025 | 219 |
| 2024 | 215 |
| 2023 | 186 |
| 2022 | 193 |
| 2021 | 230 |
| 2020 | 197 |
| 2019 | 174 |
| 2018 | 188 |
| 2017 | 207 |
Showing 10 of 34 years.
Prediction, not a registry value: median of 36 months from start to primary completion across 213 trials still running at the 2026-10-09 snapshot; registered median of 14 months across 2,592 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (1,670)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| CARBOPLATIN | Lung Neoplasms | Phase 3 | 32 |
| CARBOPLATIN | Carcinoma, Non-Small-Cell Lung | Phase 3 | 26 |
| CISPLATIN | Lung Neoplasms | Phase 3 | 23 |
| PEMETREXED | Lung Neoplasms | Phase 3 | 20 |
| PEMETREXED | Carcinoma, Non-Small-Cell Lung | Phase 3 | 18 |
Showing 5 of 1,670 active programs.
Approved assets (372)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| DURVALUMAB | 105 |
| Dapagliflozin | 93 |
| ROSUVASTATIN | 74 |
| Esomeprazole | 71 |
| OLAPARIB | 60 |
Showing 5 of 372 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 54% hit target (n=927) | 37% on time (n=878) |
Journals published in (889)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The New England journal of medicine | 169 |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 136 |
| Circulation | 122 |
| Journal of the American College of Cardiology | 93 |
| Diabetes care | 91 |
Showing 5 of 889 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 1,562 | 104 | 2025-12-30 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 58,739,000,000 | 10,233,000,000 | 14,232,000,000 |
| 2024 | 54,073,000,000 | 7,041,000,000 | 13,583,000,000 |
| 2023 | 45,811,000,000 | 5,961,000,000 | 10,935,000,000 |
| 2022 | 44,351,000,000 | 3,293,000,000 | 9,762,000,000 |
| 2021 | 37,417,000,000 | 115,000,000 | 9,736,000,000 |
| 2020 | 26,617,000,000 | 3,144,000,000 | 5,991,000,000 |
| 2019 | 24,384,000,000 | 1,227,000,000 | 6,059,000,000 |
| 2018 | 22,090,000,000 | 2,050,000,000 | 5,932,000,000 |
| 2017 | 22,465,000,000 | 2,868,000,000 | 5,757,000,000 |
| 2016 | 23,002,000,000 | 3,406,000,000 | 5,890,000,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (260)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-07-27 | Royalty / licensing | not disclosed | Sec extracted |
| 2026-07-27 | Royalty / licensing | not disclosed | Sec extracted |
| 2026-07-14 | Royalty / licensing | not disclosed | Sec extracted |
| 2026-07-01 | Other financing | not disclosed | Sec extracted |
| 2026-06-30 | Other financing | not disclosed | Sec extracted |
Showing 5 of 260 events.
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (486)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Parexel | Uses vendor | 180 |
| Parexel | Co sponsors trial with | 46 |
| Iqvia Holdings Inc. | Uses vendor | 46 |
| Government of the United States of America | Co sponsors trial with | 31 |
| Daiichi-Sankyo (Japan) | Co sponsors trial with | 25 |
Showing 5 of 486 relationships.
Latest dated events (6,910)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2027-04-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-02 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-01-30 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-01-06 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-12 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 6,910 events.
Biomarker capability evidence (11,792)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ABCA2 | Trial sponsor | Named in trial inclusion criteria |
| ABCD2 | Trial sponsor | Named in trial inclusion criteria |
| ABCG2 | Trial collaborator | Named in trial inclusion criteria |
| ABCG2 | Trial sponsor | Named in trial inclusion criteria |
| ABRAXAS1 | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 11,792 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, clia clinical laboratory certificates, and biomarkers this organization publishes on.